2024-03-28T13:54:30Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1530182021-12-28T15:33:54Zcom_10261_54com_10261_1col_10261_307
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders
Navarro, Gemma
Morales, Paula
Rodríguez-Cueto, Carmen
Fernández-Ruiz, Javier
Jagerovic, Nadine
Franco, Rafael
Fundació La Marató de TV3
Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs), namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson's disease, Huntington's chorea, cerebellar ataxia, amyotrohic lateral sclerosis). Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration. Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.
2017-07-14T11:54:43Z
2017-07-14T11:54:43Z
2016-09-13
2017-07-14T11:54:43Z
artículo
Frontiers in Neuroscience 10: 406 (2016)
1662-4548
http://hdl.handle.net/10261/153018
10.3389/fnins.2016.00406
http://dx.doi.org/10.13039/100008666
27679556
en
Publisher's version
http://dx.doi.org/10.3389/fnins.2016.00406
Sí
Copyright © 2016 Navarro, Morales, Rodríguez-Cueto, Fernández-Ruiz, Jagerovic and Franco.
http://creativecommons.org/licenses/by/4.0/
openAccess
Frontiers Media